Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.
Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.
CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.
Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.
Moosmayer is set to join the pharma company in December.
Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.
Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.
WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."
Mohan was previously head of global drug-development communications.
Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.
The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.